Andy Birchfield in the News

Photo of Andy Birchfield Andy D. Birchfield , Jr.
Lead Attorney in $4.85 Billion Vioxx Settlement
 

Articles 81 to 90 of 100 for attorney Andy Birchfield .

First Vioxx Fight: Where to Litigate

The National Law Journal | November 15, 2004
Attorneys involved in Vioxx litigation predict that all federal cases will be consolidated and transferred to a single venue soon after the Judicial Panel on Multidistrict Litigation meets in January.

Andy Birchfield Comments on Gilmartin Interview

| November 15, 2004
Attorney Andy Birchfield Jr. is directing litigation against Merck & Co. by people who alleged that the painkiller caused heart attacks or strokes.

Former Pell City Resident to Appear on '60 Minutes'

The Daily Home | November 13, 2004
Some of Pell City's citizens may recognize a familiar face if they turn on 60 minutes Sunday night.

Lawyers prepare for litigation against Merck over Vioxx

| November 12, 2004
Representatives of both the drugmaker Merck and the FDA will be on Capitol Hill next week to answer safety questions about Merck's drug Vioxx.

Lawyers meet to discuss scope of Vioxx Litigation.

| November 9, 2004
Lawyers meeting to discuss Vioxx litigation say pending lawsuits will show that Merck & Co. Inc. was aware of the arthritis drug's risks before it was taken off the market.

Lawyers Meet to Discuss Scope of Vioxx Litigation

Reuters | November 9, 2004
Lawyers meeting on Tuesday to discuss Vioxx litigation say pending lawsuits will show that Merck & Co, Inc. (MRK.N) was aware of the arthritis drug's risks before it was taken off the market.

Vioxx shockwaves rock Merck

The Trentonian | November 7, 2004
Merck & Co.'s Pandora's box has been opened wide, affecting much more than just the 20 million users of Vioxx.

Lawyers put pressure on Merck over Vioxx

The Financial Times | November 2, 2004
Plaintiffs' attorneys stepped up pressure on Merck on cases related to its withdrawal of Vioxx, the anti-inflammatory drug, sending the US drugmaker's shares plummeting again.

Merck Falls on report of Secrecy

The Record | November 2, 2004
Shares of Merck & Co. plunged again after a news report suggested the drug maker attempted to keep safety worries from hurting the prospects of Vioxx before the company finally recalled the painkiller.

News that maker hid Vioxx data sinks stock 10 percent

The Associated Press | November 2, 2004

Shares of Merck & Co. plunged more than 10 percent yesterday after a news report said documents showed the pharmaceutical giant hid or denied evidence for years that its blockbuster arthritis drug Vioxx causes heart problems.